Income Statement
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cost of Revenue | $33K | — | +312.5% |
| Gross Profit | -$33K | — | -312.5% |
| R&D Expense | $29K | — | +31.8% |
| SG&A Expense | $451K | — | +74.8% |
| Operating Income | -$513K | — | -78.1% |
| Net Income | -$921K | — | -230.1% |
| EPS (Basic) | -$0.41 | — | -4000.0% |
| EPS (Diluted) | -$0.41 | — | -4000.0% |
Balance Sheet
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $475K | -36.7% | -53.2% |
| Accounts Receivable | $16K | -61.0% | — |
| Current Assets | $813K | -10.4% | -24.3% |
| Total Assets | $1.1M | -10.6% | -16.8% |
| Current Liabilities | $1.3M | +73.4% | +282.2% |
| Total Liabilities | $1.7M | +47.1% | +122.1% |
| Stockholders' Equity | -$573K | -673.0% | -198.5% |
Cash Flow
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$517K | — | -137.2% |
| Capital Expenditures | $25K | — | +0.0% |
| Investing Cash Flow | -$25K | — | +0.0% |
| Financing Cash Flow | $275K | — | — |
| Free Cash Flow | -$542K | — | -123.0% |